checkAd
    Startseite > Aktien > Stoke Therapeutics > Nachrichten
    Stoke Therapeutics
    Aktie
    ISIN: US86150R1077 WKN: A2PLTL SYM: STOK Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    17,520
     
    USD
    +1,92 %
    +0,330 USD
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    13.06.24
    17,500
     
    USD
    4.600 STK
    Briefkurs
    13.06.24
    17,520
     
    USD
    1.200 STK

    Stoke Therapeutics Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Stoke Therapeutics to Present at Upcoming Investor Conferences in June
    03.06.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    17.05.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
    06.05.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
    29.04.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
    17.04.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
    04.04.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
    28.03.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Announces Proposed Public Offering
    26.03.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
    25.03.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    25.03.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    17.01.24 · Business Wire (engl.) · Stoke Therapeutics
    Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
    08.01.24 · Business Wire (engl.) · Stoke Therapeutics